Epoetin theta: Efficacy and safety of IV administration in anaemic haemodialysis patients in the maintenance phase in comparison to epoetin beta

Current Medical Research and Opinion

Volumn 26, Issue 10, 2010, Pages 2393-2402

  Gertz, B ^a   Kohler, E ^a   Kes, P ^b   Essaian, A ^c   Bias, P ^d   Buchner, A ^d   Elsasser R ^d  

^a BioGeneriX AG   (Germany)

^b KBC Zagreb   (Croatia)

^c PAVLOV FIRST SAINT PETERSBURG STATE MEDICAL UNIVERSITY   (Russian Federation)

^d TEVA PHARMACEUTICALS   (Israel)

Author keywords

Anaemia; Chronic kidney disease; Epoetin beta; Epoetin theta; Haemodialysis

Indexed keywords

EPOETIN THETA; FERRITIN; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTERIOVENOUS FISTULA; ARTICLE; CARDIOTOXICITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART FAILURE; HEART INFARCTION; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOGENICITY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE SPASM; NECROSIS; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; THROMBOSIS; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANEMIA; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMODIALYSIS SOLUTIONS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 77956736131     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.511084     Document Type: Article

References (14)

1. Levin A. Identification of patients and risk factors in chronic kidney disease-evaluating risk factors and therapeutic strategies. Nephrol Dial Transplant 2001;16:57-60
2. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001;37:182-238
3. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999;14:1-50
4. Locatelli F, Aljama P, Bá rány P, et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004;19:1-47
5. Eschbach JW, Egrie JC, Downing MR, et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78
6. Winearls CG, Oliver DO, Pippard MJ, et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-1178
7. Kes P, Essaian A, Gertz B. Subcutaneous epoetin theta shows a similar efficacy and safety profile as epoetin beta for a maintenance treatment of renal anaemia in pre-dialysis patients. Nieren-und Hochdruckerkrankungen 2009;38:449
8. FDA: Darbepoetin alfa, Summary Basis of Approval, 2001
9. Hörl WH, Holzer H, Mayer GJ. Treatment of renal anaemia with darbepoetin alfa-results of an Austrian multicentre study. Wien Klin Wochenschr 2002;114:967-71. In German
10. EMA, Epoetin beta, Summary of Product Characteristics, revised 11 May 2010
11. Nissenson AR, Swan SK, Lindberg JS, et al. Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kid Dis 2002;40:110-118
12. Levin NW, Fishbane S, Valdés Cañ edo F, et al. Intravenous methoxy polyethylene glycol-epoetin beta for Hb control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). Lancet 2007;370:1415-1421
13. Wizemann V, Rutkowski B, Baldamus C, et al. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Cur Med Res Opin 2008;24:625-637
14. Haag-Weber M, Vetter A, Thyroff-Friesinger U, et al. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving haemodialysis. Clin Nephrol 2009;72:380-390